Overview
OWP Pharmaceuticals’ focus is to support providers and patients in the US with beneficial medications, and to donate profits to ROW Global. ROW seeks to improve the education, diagnosis, and treatment available for those living with neurological disorders in under-resourced areas of the world. In short, OWP uses commercial success for the common good by supporting humanitarian projects in many countries.
OWP currently markets Subvenite® (lamotrigine tablets, USP) Starter Kits, which are its branded generic alternative (AB rated) to Lamictal® (lamotrigine) Starter Kits, as well as Lamotrigine Starter Kits, the generic alternative (AB rated) to Lamictal® (lamotrigine) Starter Kits. OWP offers three Starter Kits (Orange, Blue, and Green), each based on FDA-approved 5-week titration schedules, for patients initiating lamotrigine therapy.
Please see Important Safety Information for Subvenite® (lamotrigine tablets, USP), including boxed warning, indications for use, and limitations of use at www.subvenite.com.
Websites: owppharma.com and rowglobal.org
OWP Pharmaceuticals’ focus is to support providers and patients in the US with beneficial medications, and to donate profits to ROW Global. ROW seeks to improve the education, diagnosis, and treatment available for those living with neurological disorders in under-resourced areas of the world. In short, OWP uses commercial success for the common good by supporting humanitarian projects in many countries.